Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma

被引:0
|
作者
Snehal Navnath Dhumal
Sheetal Korde Choudhari
Sangeeta Patankar
Shrikrishna S. Ghule
Yogesh B. Jadhav
Sneha Masne
机构
[1] YMT Dental College and Research Institute,
来源
Head and Neck Pathology | 2022年 / 16卷
关键词
Cancer stem cells; CD44; ALDH1; Cancer stem cell markers; Oral potentially malignant disorders; Hyperkeratosis; Oral submucous fibrosis; Dysplasia; Oral squamous cell carcinoma; Lymph node metastasis;
D O I
暂无
中图分类号
学科分类号
摘要
Tumour heterogeneity in oral cancer is attributed to the presence of cancer stem cells (CSCs). CSCs are the most migratory and metastatic cellular subpopulation within tumours. Assessment of CSC markers as significant predictors of lymph node metastasis may prove valuable in the clinical setting. Furthermore, analysis of this panel of putative stem cell markers in oral dysplasia may additionally inform of the likelihood for oral potentially malignant disorders (OPMDs) to progress to oral squamous cell carcinoma (OSCC). The present study aims to assess the significance of CSC markers in the progression of OPMDs to OSCC and assessment of lymph node metastasis in OSCC. CD44 and ALDH1 were assessed immunohistochemically in 25 normal, 30 OPMDs, and 24 OSCCs. CD44 is a membranous marker and ALDH1 is a cytoplasmic marker. The immunohistochemical expression of these markers were compared between OPMDs with and without dysplasia, as well as between low-risk and high-risk dysplasias. Similarly, expression was compared between OSCC with and without lymph node metastasis and among grades of OSCC. Positive CD44 expression was seen in all normal mucosal tissues. The expression decreased from normal epithelium to OPMDs but increased in OSCC. CD44 expression was positive in 21 cases of OSCC (87.5%) and reduced from well-differentiated to poorly differentiated OSCC. CD44 staining index was higher in OSCC without lymph node metastasis (3.59) when compared with OSCC with lymph node metastasis (1.33). There was a statistically significant difference observed in the ALDH1 staining index among three groups (p < 0.05), with highest expression seen in OSCC. Within OPMDs, the ALDH1 staining index was statistically higher in OPMDs with dysplasia as compared to OPMDs without dysplasia. Furthermore, the expression was higher in OPMDs with high-risk dysplasia when compared with low-risk dysplasia, but this was not statistically significant (p = 0.82). In conclusion, The CD44 positive population possesses properties of CSCs in head and neck carcinoma, and continuous shedding could be found after CD44 down-regulation. The present study reports differences in ALDH1 expression between OPMDs with and without dysplasia, dysplastic and non-dysplastic epithelia, and low-risk and high-risk dysplasia. These findings may suggest ALDH1 as a specific marker for dysplasia. CD44 demonstrated a difference in staining index in OSCC without lymph node metastasis versus OSCC with lymph node metastasis. These findings may suggest CD44 as a marker for lymph node metastasis. Both proteins may play key roles in the tumorigenicity of CSCs in OPMDs and OSCC.
引用
收藏
页码:453 / 465
页数:12
相关论文
共 50 条
  • [1] Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma
    Dhumal, Snehal Navnath
    Choudhari, Sheetal Korde
    Patankar, Sangeeta
    Ghule, Shrikrishna S.
    Jadhav, Yogesh B.
    Masne, Sneha
    [J]. HEAD & NECK PATHOLOGY, 2022, 16 (02): : 453 - 465
  • [2] Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer
    Wakamatsu, Yuta
    Sakamoto, Naoya
    Oo, Htoo Zarni
    Naito, Yutaka
    Uraoka, Naohiro
    Anami, Katsuhiro
    Sentani, Kazuhiro
    Oue, Naohide
    Yasui, Wataru
    [J]. PATHOLOGY INTERNATIONAL, 2012, 62 (02) : 112 - 119
  • [3] CD44 and ALDH1 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma
    Ortiz, Rafael C.
    Lopes, Nathalia M.
    Amor, Nadia G.
    Ponce, Jose B.
    Schmerling, Claudia K.
    Lara, Vanessa S.
    Moyses, Raquel A.
    Rodini, Camila O.
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2018, 47 (08) : 740 - 747
  • [4] Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis
    Li, Wenzhe
    Ma, Huailei
    Zhang, Jin
    Zhu, Ling
    Wang, Chen
    Yang, Yanlian
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [5] Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis
    Wenzhe Li
    Huailei Ma
    Jin Zhang
    Ling Zhu
    Chen Wang
    Yanlian Yang
    [J]. Scientific Reports, 7
  • [6] Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer
    Tahani Louhichi
    Sonia Ziadi
    Hanene Saad
    Myriam Ben Dhiab
    Sarra Mestiri
    Mounir Trimeche
    [J]. Breast Cancer, 2018, 25 : 698 - 705
  • [7] Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer
    Louhichi, Tahani
    Ziadi, Sonia
    Saad, Hanene
    Ben Dhiab, Myriam
    Mestiri, Sarra
    Trimeche, Mounir
    [J]. BREAST CANCER, 2018, 25 (06) : 698 - 705
  • [8] Prognostic Significance of Cancer Stem Cell Markers CD44 and ALDH1 Expression in Adenocarcinoma of the Lung
    Park, K. S.
    Sung, W. J.
    Bae, C. H.
    Lee, E. B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1468 - S1468
  • [9] Author Correction: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis
    Wenzhe Li
    Huailei Ma
    Jin Zhang
    Ling Zhu
    Chen Wang
    Yanlian Yang
    [J]. Scientific Reports, 8
  • [10] The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma
    Mohamed, Salem Y.
    Kaf, Randa Mohamed
    Ahmed, Mona Mostafa
    Elwan, Amira
    Ashour, Hassan R.
    Ibrahim, Amr
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (04) : 824 - 837